

No: 15/2025/CV-VMD

About: Explaining the fluctuation of over 10% in the business performance on the separate financial statements and consolidated financial statements of the 4th quarter of 2024 compared to the 4th quarter of 2023

Ha Noi, 25. January 2025

TO: **The State Securities Commission**
Ho Chi Minh City Stock Exchange

Pursuant to the guidance in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on guidance on information disclosure on the stock market, Vimedimex Pharmaceutical Joint Stock Company (Vimedimex Company), stock code: VMD, explains the profit fluctuations in the fourth quarter of 2024 compared to the fourth quarter of 2023 on the Separate Financial Statements and Consolidated Financial Statements as follows:

Content	4th quarter of 2024	4th quarter of 2023	Difference	% Increase/Decrease
Profit after corporate income tax – Separate Financial Statements	15.615.884.363	13.123.896.670	2.491.987.693	18,99%
Profit after corporate income tax – Consolidated Financial Statements	13.491.841.190	7.186.880.006	6.304.961.184	87,73%

In the Separate Financial Statements:

Profit after corporate income tax in the fourth quarter of 2024 in the Separate Financial Report increased by **VND 2,491,987,693**, equivalent to an increase of **18.99%** over the same period in 2023, mainly due to:

- Revenue from sales and service provision activities in the 4th quarter of 2024 decreased by **VND 189,433,013,577**, equivalent to **-31.98%** compared to the same period in 2023..

- Financial operating revenue in the fourth quarter of 2024 decreased by **VND 630,025,737**, equivalent to **22.51%** compared to the same period in 2023.

- However, the company reduced costs in the fourth quarter of 2024 compared to the same period in 2023: selling expenses decreased by **VND 7.1 billion**, equivalent to **17.53%**, management expenses increased by **VND 10.2 billion**, equivalent to **249.38%**.

In the Consolidated Financial Statements:

Profit after corporate income tax in the fourth quarter of 2024 in the Consolidated Financial Statements increased by **VND 6,304,961,184**, equivalent to an increase of **87.73%** over the same period in 2023, mainly due to:

- Revenue from sales and service provision in the fourth quarter of 2024 decreased by **VND 74,145,727**, equivalent to **-0.34%** compared to the same period in 2023.

- Financial operating revenue in the fourth quarter of 2024 increased by **VND 2,325,234,299**, equivalent to **19.27%** over the same period in 2023.

- Selling expenses increased by **VND 323,189,649** equivalent to **8.9%**, management expenses decreased by **VND 80,785,746** equivalent to **-2.95%**.

Vimedimex Medi - Pharma Joint Stock Company would like to report and explain the fluctuation of over 10% in Business Performance Results on the Separate Financial Statements and Consolidated Financial Statements for the 4th Quarter of 2024 compared to the same period in 2023. Vimedimex Medi - Pharma Joint Stock Company commits that the above information is true./.

Best regards!

Recipients:

- As above;
- Board of Directors (for report);
- Archive: Clerical./.

VIMEDIMEX MEDI - PHARMA JOINT STOCK COMPANY



TỔNG GIÁM ĐỐC
Trần Mỹ Linh

